Purchase this article with an account.
U.U. Inan, F. Ozturk, S.S. Ermis, S. Yaman; The Effect of Diclofenac on the Prevention of Posterior Capsule Opacification in Human Eyes . Invest. Ophthalmol. Vis. Sci. 2004;45(13):365.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: The effects of diclofenac sodium given during the stage of hydrodissection of phacoemulsification surgery on the posterior capsule opacification (PCO) in human eyes were investigated. Methods: Eleven patients undergoing phacoemulsification in both eyes were included. The patients with pseudoexfoliation, uveitis and diabetes were excluded. Hydrodissection was done with only BSS in the first eyes. In the fellow eyes 0.25 mg/ 1 cc diclofenac was given with hydrodissection. Same intraocular lenses were implanted in both eyes of the patients. Follow–up was 21.8±3.5 months in the diclofenac group and 22.7±3.7 months in the control group. PCO was evaluated clinically by dividing posterior capsule into 24 zones. Mann–Whitney U test was used for statistical analysis. Results: There were no statistically significant differences of age, diameter of capsulorhexis, pupillary width, visual acuity, intraocular pressure and follow–up in both groups. PCO score was 0.502±0.23 in eyes receiving diclofenac and 0.722±0.21 in the contrlateral fellow eyes. Difference was not statistically significant (p:0.08). Conclusions: Diclofenac sodium given by hydrodissection in phacoemulsification decreased but not prevented significantly the development of PCO.
This PDF is available to Subscribers Only